Table 3.
Comparison of clinical features, pulmonary function tests (PFTs) according to the anti-tRNA autoantibodies.
| Variable | Anti-Jo1+ Patients n = 10 |
Anti-PL7+ Patients n = 8 |
Anti-PL12+ Patients n = 11 |
Anti-EJ+ Patients v10 |
p-Value |
|---|---|---|---|---|---|
| Age at baseline assessment | 45 ± 9.5 | 62 ± 10.7 | 51.5 ± 5.6 | 50.9 ± 7.4 | 0.002 ∃ |
| Female gender * | 9 (90%) | 7 (87.5%) | 4 (45.5%) | 9 (90%) | 0.13 |
| Pulmonary symptoms before baseline evaluation | 7.5 (2–14) | 15 (5–24) | 12 (1–20) | 12 (6–12) | 0.87 |
| Patients with ILD progression at follow-up. | 0 | 1 (12.5%) | 2 (18.18%) | 0 | 0.27 |
| Arthritis * | 10 (100%) | 5 (62%) | 8 (73%) | 5 (50%) | 0.06 |
| Mechanic’s hand sign * | 8 (80%) | 5 (62.5%) | 7 (63.6%) | 3 (30%) | 0.16 |
| Fever * | 7 (70%) | 3 (37.5%) | 4 (36.4%) | 6 (60%) | 0.37 |
| Raynaud’s phenomenon * | 6 (60%) | 3 (37.5%) | 2 (19%) | 2 (20%) | 0.18 |
| CK level at baseline *** | 516 (107–2413) | 61 (34–75.5) | 100 (50–178) | 240 (88–1652) | 0.004 |
| Anti-Ro52 positivity * | 5 (50%) | 5 (62.5%) | 8 (72.7%) | 8 (80%) | 0.55 |
| Baseline % of predicted value of FVC ** | 65 (34–76) | 75 (59–86.5) | 45 (42–64) | 44 (40–60) | 0.20 |
| Baseline % of predictive value of DLCO | 51 (38–80) | 48 (29.5–61.5) | 40 (33–55) | 45.5 (32–73) | 0.85 |
| Patients with improvement in FVC (>10%) or in DLCO (>15%) * | 6 (60%) | 4(50%) | 6 (54.5%) | 10 (100%) | 0.047 |
| Patients with lung disease progression in FVC (>10%) or in DLCO (15%) * | 0 | 1 (12.5%) | 2 (19%) | 0 | 0.27 |
| Follow-up % of predicted value of FVC | 74 (57–104) | 66 (49–95.5) | 58.5 (43–62) | 71 (43–92) | 0.35 |
| Follow-up % of predicted value of DLCO | 80 (55–119) | 70 (37–89) | 56 (40–57) | 61 (35–87) | 0.37 |
* Categorical variables are described with percentages. ** Medians (IQR). ∃ Anti-PL7+ patients are different from anti-Jo1+ and anti-Ej+ patients at baseline age evaluation, p < 0.001 and < 0.049, respectively, anti-PL7 tended be older compared to anti-PL12+ patients (p < 0.064). *** Anti-PL7 had statistically lower CK levels compared to Anti-Jo1+ (p < 0.0034), and anti-Ej (p < 0.009). Anti-PL12+ patients had lower baseline CK levels compared to anti-Jo1+ patients (p < 0.03).